Byoung Chul Cho
Hebron University(PS)Universitat Autònoma de Barcelona(ES)Yonsei University(KR)Severance Hospital(KR)Vall d'Hebron Institut de Recerca(ES)Dana-Farber Cancer Institute(US)Yonsei University Dental Hospital(KR)Korea Engineering Consultants Corporation(KR)Vall d'Hebron Hospital Universitari(ES)Gangnam Severance Hospital(KR)Yonsei University Health System(KR)Jeonju University(KR)
Publications by Year
Research Areas
Lung Cancer Treatments and Mutations, Cancer Immunotherapy and Biomarkers, Lung Cancer Research Studies, Colorectal Cancer Treatments and Studies, Lung Cancer Diagnosis and Treatment
Most-Cited Works
- → Osimertinib in Untreated EGFR -Mutated Advanced Non–Small-Cell Lung Cancer(2017)5,101 cited
- → Durvalumab after Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer(2017)4,429 cited
- → Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial(2019)3,270 cited
- → Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC(2018)2,751 cited
- → Overall Survival with Osimertinib in Untreated, EGFR -Mutated Advanced NSCLC(2019)2,707 cited
- → Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1–2 trials(2019)1,690 cited